Artificial Intelligence1 min read

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

By · Via TechCrunch · Published by Everything Blog

In short

Isomorphic Labs secured the fresh funding following positive preclinical results in its oncology and immunology programs. The company builds on the Nobel Prize-winning AlphaFold platform by using multiple simulation AI models to investigate chemical structures and engineer novel therapies. With major pharmaceutical partnerships already established alongside Eli Lilly, Novartis, and Johnson & Johnson, the capital will expand the reach of its proprietary drug-design engine.

Key points

  • Heavy backing from global venture firms demonstrates surging confidence in applying gener…: Heavy backing from global venture firms demonstrates surging confidence in applying generative protein-prediction models to clinical pipeline development.
  • Deep collaboration with major pharmaceutical partners indicates commercial readiness to t…: Deep collaboration with major pharmaceutical partners indicates commercial readiness to transition theoretical computational chemistry into clinical-stage drug testing.
  • The platform leverages the foundational AlphaFold architecture to move past protein model…: The platform leverages the foundational AlphaFold architecture to move past protein modeling into direct chemical design and treatment simulation.

Sources checked by our analysis pipeline: 1

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into…

Artificial Intelligence